SUPERNUS PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $15.48 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $15.48M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $15.91M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $15.61M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $15.42M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits as first filed |
|---|---|---|
| 2025-12-31 | $15.48M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $15.91M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $15.61M 10-K · filed 2025-02-25 | |
| 2022-12-31 | $15.42M 10-K · filed 2023-03-09 | |
| 2021-12-31 | $17.80M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $13.55M 10-K · filed 2022-04-13 | |
| 2019-12-31 | $10.35M 10-K · filed 2021-03-08 | |
| 2018-12-31 | $8.22M 10-K · filed 2020-02-28 | |
| 2017-12-31 | $7.09M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $8.13M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $5.89M 10-K · filed 2017-03-16 | $5.89M 10-K · filed 2016-03-09 |
| 2014-12-31 | $3.44M 10-K/A · filed 2017-01-20 | $3.39M 10-K · filed 2015-03-12 |
| 2013-12-31 | $1.99M 10-K · filed 2015-03-12 | |
| 2012-12-31 | $59.00K 10-K · filed 2014-03-21 | $60.00K 10-K · filed 2013-03-15 |
| 2011-12-31 | $48.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |